Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Core Points - Zentalis Pharmaceuticals granted non-qualified stock options for 35,000 shares to a newly hired employee as part of its 2022 Employment Inducement Incentive Award Plan [1][2] - The exercise price of the stock options is set at $1.68 per share, matching the closing price on the grant date, with a 10-year term and a four-year vesting schedule [3][4] Company Overview - Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing azenosertib, a WEE1 inhibitor for Cyclin E1+ platinum-resistant ovarian cancer, with ongoing clinical trials demonstrating anti-tumor activity [5]